Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02200770 · ClinicalTrials.gov registry record · Phase 2
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 231
- Enrollment target
NCT02200770 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 231 participants.
The verdict
NCT02200770, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 231 participants
- Enrollment target
Study Summary
To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
Interventions
- OTHER Placebo
- DRUG Inebilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 231 participants |
| Start Date | 2015-04-01 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02200770
The ClinicalTrials.gov registry entry for NCT02200770 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 231 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02200770 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02200770 about?
NCT02200770 is a clinical study titled "N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders". To compare the efficacy of inebilizumab (MEDI-551) versus placebo in reducing the risk of an neuromyelitis optica/neuromyelitis optica- spectrum disorders (NMO/NMOSD) attack in participants with NMO/NMOSD.
What is the current status of trial NCT02200770?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 231 participants. The study started on 2015-04-01. Estimated completion is 2020-11-06.
What interventions are being tested in trial NCT02200770?
The interventions under investigation include: Placebo (OTHER), Inebilizumab (DRUG).
Who is sponsoring clinical trial NCT02200770?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.